Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01187199 · ClinicalTrials.gov registry record · Phase 1
Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer
A Phase 1 study of Advanced Cancer, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- Phase 1
- Development phase
- 278
- Enrollment target
- 1
- Study location
NCT01187199: Active Phase 1 study of Advanced Cancer, sponsored by M.D. Anderson Cancer Center.
NCT01187199 is a Phase 1 study of Advanced Cancer that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 278 participants, above the 244-participant average among 122 other Advanced Cancer trials with a reported enrollment target (14% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01187199, a Phase 1 study of Advanced Cancer, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 278 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical research study is to find the highest tolerable dose of the combination of bevacizumab (Avastin) and temsirolimus (Torisel) that can be given with 1 of 3 other study drugs --carboplatin (Paraplatin), paclitaxel (Taxol), or sorafenib (Nexavar). The safety of these drug combinations will also be studied.
Primary Outcome
MTD defined by dose-limiting toxicities (DLTs) that occur during the first four weeks of therapy. DLT defined as any grade 3 or 4 non-hematologic toxicity as defined in NCI CTC v4.0.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Carboplatin
- DRUG Paclitaxel
- DRUG Sorafenib
- DRUG Temsirolimus
Study Locations (1)
Texas
- University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 278 participants |
| Start Date | 2010-08-19 |
| Est. Completion | 2026-04-30 |
| Phase | Phase 1 |
What the registry record for NCT01187199 still lists
NCT01187199 is an interventional study that assigns participants to a tested intervention. The registered 278 participants enrollment target is mid-sized for trials with a published cap, above the 244-participant average among 122 other Advanced Cancer trials with a reported enrollment target (14% higher).
The record links to 1 condition, with Advanced Cancer appearing as the primary indexed condition, and to 5 interventions - of which Bevacizumab is the first listed.
NCT01187199 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT01187199 about?
NCT01187199 is a clinical study titled "Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer". The goal of this clinical research study is to find the highest tolerable dose of the combination of bevacizumab (Avastin) and temsirolimus (Torisel) that can be given with 1 of 3 other study drugs --carboplatin (Paraplatin), paclitaxel (Taxol), or sorafenib (Nexavar). The safety of these drug combi...
What is the current status of trial NCT01187199?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 278 participants. The study started on 2010-08-19. Estimated completion is 2026-04-30.
What conditions does trial NCT01187199 study?
This clinical trial studies the following conditions: Advanced Cancer.
What interventions are being tested in trial NCT01187199?
The interventions under investigation include: Bevacizumab (DRUG), Carboplatin (DRUG), Paclitaxel (DRUG), Sorafenib (DRUG), Temsirolimus (DRUG).
Who is sponsoring clinical trial NCT01187199?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01187199 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01187199's enrollment target sits among peer trials
278 22nd of 122 higher than 101 of 122 other Advanced Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss
RECRUITING · Phase 1
-
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study in Patients With Advanced Cancers
RECRUITING · Phase 1
-
A Study of MGC026 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04586959 · 278 participants · NA
Uterine Manipulation During Minimally Invasive Surgery for Early Stage Endometrial Cancer
- NCT05010148 · 278 participants · Phase 3
A Clinical Trial of Intravenous Lidocaine After Spinal Surgery to Prevent Delirium and Reduce Pain
- NCT05489237 · 278 participants · Phase 1
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
- NCT05965245 · 278 participants · NA
Suubi-Mhealth: A Mobile Health Intervention to Address Depression Among Youth
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI